Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Cilengitide is a selective αvβ3 and αvβ5 integrin inhibitor. Data from phase 2 trials suggest that it has antitumour activity as a single agent in recurrent glioblastoma and in combination with standard temozolomide chemoradiotherapy in newly diagnosed glioblastoma (particularly in tumours with methylated MGMT promoter). We aimed to assess cilengitide combined with temozolomide chemoradiotherapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Oncol.

Title: The Lancet. Oncology

ISSN (Electronic): 1474-5488

ISSN (Print): 1470-2045

Publication date (Electronic): Sep 2014

Volume: 15

Issue: 10

Affiliations

[1 ] UniversitätsSpital Zürich, Zurich, Switzerland; Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland. Electronic address: roger.stupp@usz.ch.

[2 ] Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.

[3 ] EORTC Headquarters, Brussels, Belgium.

[4 ] Edinburgh Cancer Centre, University of Edinburgh, Edinburgh, UK.

[5 ] Sunnybrook Health Sciences Centre, Toronto, ON, Canada.

[6 ] The Catholic University of Korea, Seoul St Mary's Hospital, Seoul, South Korea.

[7 ] The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

[8 ] Department of Neuropathology, Universität Bonn, Bonn, Germany.

[9 ] Clinic for Neurosurgery, Clinical Center Serbia and Medical Faculty University of Belgrade, Belgrade, Serbia.

[10 ] Klinikum der J W Goethe Universität Frankfurt, Frankfurt, Germany.

[11 ] Heidelberg University Medical Center & German Cancer Research Center, Heidelberg, Germany.

[12 ] Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology Gliwice Branch, Gliwice, Poland.

[13 ] Samsung Medical Center, Sungkyunkwan Univ School of Medicine, Seoul, South Korea.

[14 ] Universitätsklinikum Regensburg, Regensburg, Germany.

[15 ] Universitätsklinikum Freiburg, Freiburg, Germany.

[16 ] Medical Center Haaglanden, The Hague, Netherlands.

[17 ] Taichung Veterans General Hospital, Taichung, Taiwan.

[18 ] Bangalore Institute of Oncology, Bangalore, India.

[19 ] Szegedi Tudományegyetem, Szeged, Hungary.

[20 ] Tata Memorial Centre, Navi Mumbai, India.

[21 ] Universitätsklinikum Leipzig, Leipzig, Germany.

[22 ] Greater Poland Cancer Centre, Poznań, Poland.

[23 ] The Christie NHS FT, Manchester, UK.

[24 ] Bellaria-Maggiore Hospital, AUSL-IRCCS Institute of Neurological Sciences-Bologna, Italy.

[25 ] Klinikum der Universität München, München, Germany.

[26 ] University Hospital Ulm, Ulm, Germany.

[27 ] Seoul National University Bundang Hospital, SNU College of Medicine, Seoul, South Korea.

[28 ] University of Alabama at Birmingham, Birmingham, AL, USA.

[29 ] Dana-Farber Cancer Institute, Boston, MA, USA.

[30 ] Erasmus MC-Cancer Institute, Rotterdam, Netherlands.

[31 ] Merck KGaA, Darmstadt, Germany.

[32 ] UniversitätsSpital Zürich, Zurich, Switzerland.

Article

Publisher Item ID: S1470-2045(14)70379-1

DOI: 10.1016/S1470-2045(14)70379-1

PubMed ID: 25163906

SO-VID: cdfa3eca-5f67-4413-91bd-91eaa31d23a8

History

Data availability:

Comments

Comment on this article

scite_

Cited by 361

See all cited by

- Version 1